EC
RLAY icon

EntryPoint Capital’s Relay Therapeutics RLAY Stock Holding History

EntryPoint Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,236
Closed -$281K – 889
2025
Q4 		$281K Sell
33,236
-17,681
-35% -$126K 0.11% 392
2025
Q3 		$266K Buy
50,917
+3,958
+8% +$15.1K 0.1% 415
2025
Q2 		$162K Sell
46,959
-24,527
-34% -$73K 0.08% 522
2025
Q1 		$187K Buy
71,486
+49,161
+220% +$193K 0.09% 553
2024
Q4 		$92K Sell
22,325
-4,043
-15% -$22K 0.04% 674
2024
Q3 		$187K Buy
26,368
+3,101
+13% +$23.2K 0.11% 491
2024
Q2 		$152K Buy
23,267
+23,036
+9,972% +$157K 0.07% 565
2024
Q1 		$1.92K Buy
+231
New +$2.25K ﹤0.01% 1343

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

EntryPoint Capital's RLAY Position: Q1 2026 in Review

EntryPoint Capital sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 33,236 shares — an estimated $281K sold.

EntryPoint Capital first reported a position in RLAY in Q1 2024 and held it in 8 quarters. The position peaked at $281K in Q4 2025. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • EntryPoint Capital reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 33,236 Relay Therapeutics shares in Q1 2026, an estimated $281K.
  • EntryPoint Capital first reported a position in Relay Therapeutics in Q1 2024 and held it in 8 quarters.
  • EntryPoint Capital's Relay Therapeutics position peaked at $281K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.